Loading ALNY detail
Loading ticker data...
Loading ALNY detail
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics.
It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Chart data unavailable
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) insider Melissa Mclaughlin sold 1,624 shares of the business's stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $319.59, for a total value of $519,014.16. Following the transaction, the insider directly owned 11,729 shares in the company,
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) insider Melissa Mclaughlin sold 2,286 shares of the company's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the transaction, the insider owned 9,443 shares of the company's stock,
Investors need to pay close attention to ALNY stock based on the movements in the options market lately.
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new clinical and real-world data from its cardiovascular (CV) portfolio presented at the American College of Cardiology's Annual Scientific Session and Expo (ACC.26), reinforcing the potential of RNAi to deliver fundamentally differentiated, effective, and durable impact for patients living with cardiovascular disease (CVD). New data continue to support the use.
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses Progress and Strategy in Transforming ATTR Amyloidosis Care and Expanding TTR Franchise Transcript
Congress Asset Management Co. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 126.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 269,239 shares of the biopharmaceutical company's stock after buying an additional 150,439 shares during
SAN FRANCISCO--(BUSINESS WIRE)-- #ai--Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a partnership with Alnylam Pharmaceuticals, the leading RNAi therapeutics company, to accelerate early identification and standardize diagnostic evaluation of patients with cardiac amyloidosis, a serious and underdiagnosed cause of heart failure. Cardiac amyloidosis is a progressive condition in which misfolded proteins deposit in the heart muscle, leading to heart failure a.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recognition and improve care coordination for patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). Through complementary initiatives with Viz.ai and the American Heart Association, Alnylam is advancing a comprehensive, system‑level approach to address.
ALNY's strong drug sales and advancing pipeline, including late-stage candidates, are driving momentum and supporting its long-term growth outlook.
Bamco Inc. NY bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,500 shares of the biopharmaceutical company's stock, valued at approximately $1,596,000. Several other institutional investors have also
Pre-Market Stock Futures: The futures are trading higher as we start the new trading week. There is an old saying, "Fool me once, shame on you; fool me twice, shame on me." Well, the buy-the-dip crowd continued to get a masterclass in just that lesson on Friday. Once again, the stock market opened higher, and... Here Are Monday's Top Wall Street Analyst Research Calls: Alnylam Pharmaceuticals, Circle Internet, Fifth Third Bancorp, Intuit, ServiceNow, Qualcomm, Trade Desk, and More.
Anchor Investment Management LLC grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 1,024.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,249 shares of the biopharmaceutical company's stock after acquiring an additional 2,049 shares during the period.
Investing in equities involves accepting volatility as the cost of long-term compounding. In 15 significant systemic shocks during which Alnylam Pharmaceuticals (ALNY) was traded, the stock experienced an average drawdown of -25%.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming TTR Investor Webinar on the Investors section of the Company's website, www.alnylam.com, on Tuesday, March 24, 2026 at 9:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. The TTR Investor Webinar, marking one year since U.S. FDA approval of AMVUTTRA® in ATTR-CM, will highlight Alnylam'.
